Zoetis Inc. Q3 2026 Earnings Recap

Investors were disappointed by continued weakness in companion animal demand and competition in key franchises; Zoetis shares fell 7.9% after earnings. U.S. clinic visits were down 3% year to date, while the company said third-quarter revenue and adjusted net income declined in line with its expectations.

Key Takeaways

• Management cited rising veterinary costs, softer consumer confidence and changing pet ownership patterns as pressures on care demand; veterinary service costs in developed pet markets have risen 50% since 2022.
• Companion animal revenue remained under pressure, with competition particularly acute in dermatology.
• Zoetis narrowed full-year revenue guidance to the high end of its existing range; the transcript does not provide a revised growth figure.
• Livestock benefited from demand for quality protein and animal-health productivity, though management noted disease, weather and local production cycles can affect results.